Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
September 4, 2008

Tocris to Provide Gefitinib for Preclinical Cancer Research

  • Tocris Bioscience signed an exclusive deal with AstraZeneca to supply Gefitinib (also known as Iressa™ and ZD1839) to preclinical researchers working on the mechanisms underlying cancer development. Strict conditions have been imposed by AstraZeneca to ensure that it is not used in human studies, notes Duncan Tocris.

    For the first time, scientists will be able to buy authentic, fully licensed, nonformulated Gefitinib as an off-the shelf product for use in biological research, according to Tocris.

    Gefitinib targets and blocks the activity of the EGFR-TK (epidermal growth factor tyrosine kinase), an enzyme that regulates intracellular signaling pathways implicated in cancer cell proliferation and survival. It is approved for the treatment of advanced non-small-cell lung cancer (NSCLC) in 36 countries.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.